Steven Watkins
Amministratore Delegato presso BCD Bioscience, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Carlito Lebrilla | M | - |
BCD Bioscience, Inc.
 BCD Bioscience, Inc. BiotechnologyHealth Technology BCD Bioscience, Inc. is a biotechnology company, which engages in the creation of oligosaccharide library. It also designs a roadmap that connects carbohydrate structures with its functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. The company was founded by Carlito Lebrilla, David Mills, and Bruce German in 2019 and is headquartered in Davis, CA. | 5 anni |
| Oxana Kukhaneva | F | - |
BCD Bioscience, Inc.
BCD Bioscience, Inc. BiotechnologyHealth Technology BCD Bioscience, Inc. is a biotechnology company, which engages in the creation of oligosaccharide library. It also designs a roadmap that connects carbohydrate structures with its functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. The company was founded by Carlito Lebrilla, David Mills, and Bruce German in 2019 and is headquartered in Davis, CA. | 4 anni |
| Gareth Asten | M | - |
BCD Bioscience, Inc.
BCD Bioscience, Inc. BiotechnologyHealth Technology BCD Bioscience, Inc. is a biotechnology company, which engages in the creation of oligosaccharide library. It also designs a roadmap that connects carbohydrate structures with its functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. The company was founded by Carlito Lebrilla, David Mills, and Bruce German in 2019 and is headquartered in Davis, CA. | - |
| Danilo Massari | M | - |
BCD Bioscience, Inc.
BCD Bioscience, Inc. BiotechnologyHealth Technology BCD Bioscience, Inc. is a biotechnology company, which engages in the creation of oligosaccharide library. It also designs a roadmap that connects carbohydrate structures with its functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. The company was founded by Carlito Lebrilla, David Mills, and Bruce German in 2019 and is headquartered in Davis, CA. | 4 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Ryan Davis | M | - |
Lipomics Technologies, Inc.
 Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | 9 anni |
| Alan C. Mendelson | M | 76 |
University of California, Davis
| 3 anni |
| Baron Davis | M | 44 |
University of California, Davis
| 2 anni |
| Phil Kelly | M | 64 |
University of California, Davis
| - |
| Rafael Garcia | M | - |
University of California, Davis
| 5 anni |
| Dan Adams | M | - |
University of California, Davis
| 4 anni |
| Jaime Ann Simon | F | - |
University of California, Davis
| 4 anni |
| Ariane Bertrand | F | - |
University of California, Davis
| 4 anni |
| David William Schauer | M | - |
University of California, Davis
| 4 anni |
| Li Wang | M | 55 |
University of California, Davis
| 2 anni |
| Edward Hamati | M | - |
University of California, Davis
| 5 anni |
| Marc Robert | M | 50 |
University of California, Davis
| 6 anni |
| Braxton Zink | M | - |
University of California, Davis
| 4 anni |
| William Weber | M | - |
University of California, Davis
| 3 anni |
| Michael Marquez | M | 51 |
University of California, Davis
| 4 anni |
| Asher Qureshi | M | - |
University of California, Davis
| 4 anni |
| Robin Ritter | M | - |
University of California, Davis
| 4 anni |
| Douglas S. Eisinger | M | - |
University of California, Davis
| 13 anni |
| Paul Esajian | M | - |
University of California, Davis
| 4 anni |
| Tim Freeman | M | - |
University of California, Davis
| 2 anni |
| Mariam Maghribi | M | - |
University of California, Davis
| 5 anni |
| Brian P. Lupien | M | 82 |
University of California, Davis
| 4 anni |
| Erin M. Randolph | F | - |
University of California, Davis
| 4 anni |
| Joe Merrill | M | - |
University of California, Davis
| 3 anni |
| Toby Kurth | M | - |
University of California, Davis
| 4 anni |
| Mark Mangilit Mangilit | M | - |
University of California, Davis
| 4 anni |
| James Evangelista | M | - |
University of California, Davis
| 4 anni |
| Greg Thomas | M | - |
University of California, Davis
| 2 anni |
| Ted Chen | M | - |
University of California, Davis
| 4 anni |
| Kristin Richards | F | - |
University of California, Davis
| 4 anni |
| Philip Jessop | M | - |
University of California, Davis
| 7 anni |
| Glen Evans | M | - |
University of California, Davis
| 4 anni |
| Elizabeth Loboa | M | 57 |
University of California, Davis
| 4 anni |
| Zheng Wei | M | 61 |
University of California, Davis
| 3 anni |
| Lambert Shiu | M | 44 |
University of California, Davis
| 4 anni |
| Ronnie Wong | M | 49 |
University of California, Davis
| 4 anni |
| Keeley Aleman | F | - |
University of California, Davis
| 4 anni |
| Scott Alan de Haai | M | - |
University of California, Davis
| 4 anni |
| Betsy Santos | F | - |
University of California, Davis
| 4 anni |
| Kimberly Budil | M | - |
University of California, Davis
| 3 anni |
| Wade Diebner | M | - |
University of California, Davis
| 4 anni |
| Mark Lawrence | M | 54 |
University of California, Davis
| 2 anni |
| Marcela Anongos | F | - |
University of California, Davis
| 4 anni |
| William Wayne Colston | M | 56 |
University of California, Davis
| 3 anni |
| Mina Park | F | - |
University of California, Davis
| 4 anni |
| Ali Arjomand | M | - |
University of California, Davis
| 3 anni |
| Gary Gershony | M | 68 |
University of California, Davis
| 4 anni |
| David A. Bell | M | - |
University of California, Davis
| 3 anni |
| Scott Lenet | M | - |
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | - |
| Henry S. Newhall | M | - |
University of California, Davis
| 4 anni |
| Michael Downing | M | - |
University of California, Davis
| 5 anni |
| Roger Salquist | M | - |
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | - |
| Irene Rombel | M | - |
University of California, Davis
| 2 anni |
| Evan C. Johnson | M | - |
University of California, Davis
| 4 anni |
| Yick Ming Wong | M | 72 |
University of California, Davis
| 3 anni |
| Eric Lofgren | M | - |
University of California, Davis
| 4 anni |
| Michael J. Miille | M | - |
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | - |
| Freddy Huynh | M | - |
University of California, Davis
| 4 anni |
| Karthik Narayanan | M | - |
University of California, Davis
| 1 anni |
| Edward Hoyt | M | - |
University of California, Davis
| 4 anni |
| Kevane A. Wong | M | - |
University of California, Davis
| 2 anni |
| Justin Michael Kass | M | - |
University of California, Davis
| 4 anni |
| Joncarlo Mark | M | - |
University of California, Davis
| 2 anni |
| Lance Borene Swanson | M | - |
University of California, Davis
| 4 anni |
| Alexander P. Kazan | M | - |
University of California, Davis
| 4 anni |
| Michael P. Wallace | M | - |
University of California, Davis
| 2 anni |
| Sean Anthony Lynch | M | - |
University of California, Davis
| 3 anni |
| Phan Le | M | - |
University of California, Davis
| 4 anni |
| Jennifer Schilling | F | - |
University of California, Davis
| 4 anni |
| Greg McDowell | M | - |
University of California, Davis
| 2 anni |
| Joel Gragg | M | - |
University of California, Davis
| 4 anni |
| Khang Tran | M | - |
University of California, Davis
| 4 anni |
| Robert Hulse | M | - |
University of California, Davis
| 3 anni |
| Rachel H. Kravitz | M | - |
University of California, Davis
| 3 anni |
| Richard H. DiStefano | M | 47 |
University of California, Davis
| 4 anni |
| Jeffrey T. Hartlin | M | - |
University of California, Davis
| 4 anni |
| Rajesh Patel | M | - |
University of California, Davis
| 5 anni |
| Catherine Jhung | F | - |
University of California, Davis
| 4 anni |
| Michelle Wiest | M | - |
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | 5 anni |
| Jeffrey McDonald | M | - |
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | 8 anni |
| Sarina Chohan | F | - |
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | 7 anni |
| Anula Kusum Jayasuriya | M | 67 |
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | - |
| Patrick B. Rien | M | - |
University of California, Davis
| 4 anni |
| Jason McCandless | M | - |
University of California, Davis
| 3 anni |
| Darren Waddell | M | - |
University of California, Davis
| 4 anni |
| Carolyn Powell | F | - |
University of California, Davis
| 4 anni |
| Tanya Harding | F | - |
University of California, Davis
| 5 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 91 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Steven Watkins
- Contatti personali
